ASLAN Falls As TreeTopp BTC Study Fails
TreeTopp Varlitinib Trial In Biliary Tract Cancer Missed Endpoints
Executive Summary
ASLAN’s pivotal Phase II TreeTopp study of varlitinib in biliary tract cancer missed its co-primary endpoints of progression-free survival and overall response rate.